Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
Boehringer Ingelheim is the second largest animal health business in the world. The company is committed to creating animal wellbeing through its large portfolio of advanced, preventive healthcare products and services. With net sales of €3.9 billion and around 10,000 employees worldwide, it is present in more than 150 markets.
Role of Boehringer Ingelheim in VAC2VAC
In line with other industry partners, Boehringer Ingelheim will provide technical support by product and process knowledge, including manufacturing operations as well as regulatory procedures. For the research, development and validation, this means generation and provision of samples dedicated to the specific needs. When an alternative method will be ready, the technical support will include the transfer of the method and the generation of in-house data. For validation and promotion to regulatory acceptance, we will share experience in regulatory documentation and contribute to define validation criteria, study design and facilitate the data-based discussion between stakeholders.
Dr. Elisabeth Kamphuis (International Regulatory Affairs Business Operations) has 10 years of experience at the Paul-Ehrlich-Institut, including 3Rs for rabies vaccine testing and corresponding European Pharmacopeia and OIE monograph revisions. At BI, she worked in Guadalajara, Mexico, and in Regulatory Affairs in Germany. Elisabeth leads VAC2VAC at BI.
Dr. Larry Bondoc (Bioprocess Sciences) is involved in biologics development and manufacturing in the US for over 20 years, including biodefense (anthrax and botulinum) and commercial (chlamydia and H. pylori) vaccines. At BI, he works in St. Joseph, USA, on 3R alternatives and improvement to Quality Control testing. Larry co-leads work package 3 (Immunology).